Parkinson’s disease is the second leading neurodegenerative disorder in the world that results in bradykinesia and tremor due to the death of dopaminergic neurons. Yet, it is still a challenge to select the best individual treatment and to predict the progression of the disease. Recently, miRNA (microRNA) interference has been extensively studied due to it’s affects in many biological processes, including their role in neurodegenerative diseases. MiRNAs originated from extracellular vesicles (EV) are expected to help differentiate diseases, determine their severity and progression, also to select the best treatment option based on individual miRNA profile. The aim of this study was to evaluate EV miR-23a-3p, miR-494-3p, miR-19b-3p and miR-96-5p expression levels in the serum of patients with PD and check for relations with patient data. EV miRNA’s were isolated from blood serum, transcribed into cDNA and its expression was measured by RT-PCR. Statistical analysis was performed using GraphPad Software Inc. Prism 8. MiRNA profile was evaluated by age, sex, the onset of the disease, its duration, severity of symptoms and selected method of treatment for 88 individuals with PD. 36 patients received medicational treatment, 39 underwent deep brain stimulation and 13 had gamma knife surgery. The results revealed that patients showed differently expressed miRNA levels when comparing medicational treatment group to surgical treatment groups. MiR-23a-3p expression increased as symptoms of bradykinesia become more severe. On the contrary, miR-494-3p levels were decreasing as Parkinson‘s symptoms increase, but no statistical significance was observed. Patients age, the onset of the disease and disease duration had no significant influence in miRNA levels. Association of gender and miRNA expression revealed that miR-19b and miR-23a levels were higher in men population. Furthermore, miR-23a and miR-494 expression decreased after gamma knife surgery. However, patients who received deep brain stimulation surgery did not show changes in selected miRNA profile. In conclusion, primary data suggest that different miRNA expression levels show patient heterogeneity and indicate a potential role of miRNA‘s in PD pathogenesis. However, more research is needed to further evaluate the potential of miRNAs as candidate biomarkers before application in clinical practice.